Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Free Cash Flow (2021 - 2025)

InMed Pharmaceuticals (INM) has 5 years of Free Cash Flow data on record, last reported at -$2.4 million in Q4 2025.

  • For Q4 2025, Free Cash Flow rose 5.03% year-over-year to -$2.4 million; the TTM value through Dec 2025 reached -$7.4 million, down 1.77%, while the annual FY2025 figure was -$7.8 million, 11.03% down from the prior year.
  • Free Cash Flow reached -$2.4 million in Q4 2025 per INM's latest filing, down from -$1.6 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$689750.0 in Q2 2023 and bottomed at -$5.4 million in Q1 2022.
  • Average Free Cash Flow over 5 years is -$2.3 million, with a median of -$2.1 million recorded in 2023.
  • Peak YoY movement for Free Cash Flow: surged 82.96% in 2023, then crashed 72.81% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$3.3 million in 2021, then rose by 18.26% to -$2.7 million in 2022, then surged by 31.88% to -$1.8 million in 2023, then plummeted by 35.39% to -$2.5 million in 2024, then grew by 5.03% to -$2.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$2.4 million in Q4 2025, -$1.6 million in Q3 2025, and -$1.8 million in Q2 2025.